1460 / 1835
The Evolution of Consolidation RT in Advanced-Stage HL
• RT to All disease sites (EORTC H34)
• RT to Initial bulky by CT (Stanford V, U.S. Intergroup)
• RT to Initial bulk and residual CT (HD-9, UK LY09)
•
Interim PET Response (RATHL) – No RT (most)
•
New Drug Combinations like Brentuximab-AVD
(ECHELON)
By Disease Parameters or by Response Criteria